Niger has become the latest West African country to roll out malaria vaccines to try to stifle the potentially deadly disease ...

The inoculation campaign is expected to lower the mortality rate in children, as malaria makes up 19 percent of child deaths ...

Topline results were announced from a phase 3 study assessing the immune response following coadministration of Arexvy and Shingrix.

GSK plc GSK announced positive topline results from a phase III study evaluating the co-administration of its two marketed ...

GSK plc (LSE/NYSE: GSK) today announced positive topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, reactogenicity and safety of AREXVY (Respiratory ...

A study investigating GSK’s investigational herpes simplex virus (HSV) vaccine candidate failed to meet its primary efficacy endpoint.

With the expiration of a contract to produce antibiotic medicines for Sandoz, GSK will shutter a 75-year-old manufacturing ...

Pharmaceutical companies are currently developing everything from personalized cancer vaccines that could cost tens of thousands per patient to vaccines that prevent developing-world diseases like ...

Uganda, like Cote d’Ivoire, will be among the first countries to deploy the Malaria Vaccine which, according to the Health Ministry, is set to be rolled out in April 2025.The Uganda Virus ...

showing very encouraging results and paving the way for future malaria vaccine development. A robust industrial partner, GSK Biologicals, has shown commitment to the project for more than 20 years ...

As updated coronavirus vaccines hit U.S. pharmacy shelves, adults without health insurance are discovering the shots are no longer free, instead costing up to $200. The federal Bridge Access ...

The updated vaccine is authorized for use in individuals 12 years of age and older and will target the JN.1 strain of the virus. "Today's authorization provides an additional COVID-19 vaccine ...